Correction to the Article "Diagnosis of Chronic Kidney Disease in Adults in Portugal: Practical Recommendations from National Clinical and Laboratory Experts"
DOI:
https://doi.org/10.20344/amp.24105Keywords:
Albuminuria, Glomerular Filtration Rate, Portugal, Renal Insufficiency, Chronic/diagnosisAbstract
Following publication of the original article, the authors identified an error in the content. The corrected text is presented in the PDF. The original article has also been corrected.
Chronic kidney disease represents a significant public health issue, affecting approximately 9.8% of the adult population in Portugal. Despite this figure, early diagnosis of this disease in high-risk groups remains limited. Although only two parameters are essential for its diagnosis – estimated glomerular filtration rate (eGFR) and albuminuria – in Portugal, over 50% of stage 3 - 5 patients have not undergone simultaneous assessment of eGFR and albuminuria. The insufficient implementation of the simultaneous assessment of these two metrics results in an inadequate evaluation of high-risk populations. A task force of 17 Portuguese experts from the main medical specialties involved in chronic kidney disease management (Nephrology and Family Medicine) and in Clinical Pathology/Laboratory Medicine (representatives of major national laboratories) convened to develop guidelines aimed at standardizing procedures for the prescribing, determination, reporting, and interpretation of diagnostic parameters (albuminuria and eGFR based on serum creatinine) in Portugal. This effort is based on clinical practice, scientific knowledge, and international recommendations. This national consensus among the key stakeholders in the chronic kidney disease screening and diagnosis process culminated in the development of four practical guidelines. These guidelines will enable the consistent provision of eGFR and albuminuria measurements, regardless of the attending physician’s medical specialty, the laboratory, or geographic location. Additionally, through this collective effort, experts want to raise awareness among national authorities to the need of developing new guidelines, based on scientific evidence and clinical practice, to address the underassessment of albuminuria and eGFR in this disease’s management.
Downloads
References
Sundstrom J, Bodegard J, Bollmann A, Vervloet MG, Mark PB, Karasik A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2.4 million patients from 11 countries: The CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.
Santos-Araujo C, Mendonca L, Carvalho DS, Bernardo F, Pardal M, Couceiro J, et al. Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population. Clin Kidney J. 2023;16:111-24.
Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607-18.
Golestaneh L, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Romero A, et al. All-cause costs increase exponentially with increased chronic kidney disease stage. Am J Manag Care. 2017;23:S163-72.
Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117-314.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737-49.
Gansevoort RT, Anders HJ, Cozzolino M, Fliser D, Fouque D, Ortiz A, et al. What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant. 2023;38:1-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
